Abstract
It has been experimentally proven that high doses of the reduced folate leucovorin (LV) enhance the therapeutic efficacy of 5-fluorouracil (5FU) by increasing the FdUMP-TS binding. This rationale prompted various phase II clinical trials whose results apparently showed enhancement of the 5FU antitumor activity.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Plenum Press, New York
About this chapter
Cite this chapter
Nobile, M.T. et al. (1988). A Randomized Trial of 5-Fluorouracil Alone Versus 5-Fluorouracil and High Dose Leucovorin in Untreated Advanced Colorectal Cancer Patients. In: Rustum, Y., McGuire, J.J. (eds) The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy. Advances in Experimental Medicine and Biology, vol 244. Springer, New York, NY. https://doi.org/10.1007/978-1-4684-5607-3_22
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5607-3_22
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4684-5609-7
Online ISBN: 978-1-4684-5607-3
eBook Packages: Springer Book Archive